Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
Gustavo SchvartsmanJunsheng MaRoland L BassettLauren E HayduRodabe Navroze AmariaPatrick HwuMichael K WongWen-Jen HwuAdi DiabSapna Pradyuman PatelMichael A DaviesNelson HamerschlakHussein Abdul-Hassan TawbiIsabella C Glitza OlivaPublished in: Cancer (2019)
Anti-PD-1 therapy may change the natural history of patients with preexisting MBM. However, CNS failure during treatment with anti-PD-1 is predictive of a worse prognosis compared with extracranial progression. The results of the current study support the activity of anti-PD-1 in patients with MBM, although routine CNS imaging during therapy is warranted.